The George Institute For Global Health
United Kingdom

George Health Enterprises

Early in 2013, The George Institute’s Board of Directors approved the establishment of George Health Enterprises as a separately incorporated entity responsible for all commercial activities arising from the Institute’s research programs.

George Health Enterprises consists of three divisions:

  • George Clinical
  • George Care
  • George Medicines

Each division provides commercial expertise, strategic direction and policy advice to develop new projects that will finance The George Institute.

George Clinical

George Clinical is a strategic enterprise established by The George Institute to design and manage large-scale clinical trials both for the Institute itself and for pharmaceutical and medical research organisations worldwide.

Leading CRO in the Asia Pacific Region

George Clinical offers all the essential elements required to conduct high-quality international clinical trials, including world-class scientific expertise, sophisticated project management, comprehensive study monitoring services, state-of-the-art data management facilities and biostatistics expertise.

George Clinical has offices throughout the Asia Pacific region and established partnerships with similar organizations in North American and Europe. In this way George Clinical provides a comprehensive service with truly global reach. Current clients of George Clinical include several major pharmaceutical companies from Europe and the United States.

George Clinical is wholly owned by The George Institute, and many Institute staff members work on George Clinical projects. Any profits generated by George Clinical are returned to The George Institute to support its work around the world.

For more details or to contact George Clinical please visit the George Clinical website.

George Care

George Care is a healthcare business focused on the development of innovative systems for the delivery of high-quality evidence-based medical care to patients with common chronic diseases in emerging markets. The business is built on four main platforms:

  1. an integrated clinical operating model that involves non-physician healthcare workers, pharmacists and medical practitioners working together in a highly cost- effective hub-and-spoke model
  2. a sophisticated cloud-based IT system (SMARThealth System) that gives healthcare providers mobile applications designed to guide all aspects of patient assessment, diagnosis and treatment (including the management of multiple coexisting conditions), and gives patients fully integrated applications to support self-care and home monitoring
  3. a continuous quality management program that monitors the performance of all healthcare providers and outcomes among patients
  4. a world- class international medical faculty that is continuously engaged in the development of George Care clinical programs including the large research program that underpins the SMARThealth System.

The goal of George Care is the delivery of “specialist-quality” care at a comparatively low price point for patients with (or at very high risk of) a range of adult diseases responsible for large proportions of premature death and disability. In the first instance, George Care is focused on the management of cardiometabolic conditions including diabetes, hypertension, coronary heart disease, cerebrovascular disease and chronic kidney disease.

A large Australian trial of a prototype of the SMARThealth System among patients at high risk of heart disease and stroke demonstrated clear improvements in care and better clinical outcomes among those previously treated inadequately. Trials of newer versions of the SMARThealth System have recently been launched in India and Australia, and a large trial of a family carer application is underway in China. Development partnerships have been established with Qualcomm in China, Pfizer in India and Indonesia, and Telstra in Australia. To date, more than $15 million has been spent on R&D.

George Medicines

George Medicines is focused on developing innovative combination medications using existing proven drugs. The ultimate aim is to provide cost effective solutions and improved health outcomes for patients who are currently not receiving recommended medications long-term.

Improving access and reducing costs

George Medicines aims to create solutions that help improve access for under-treated and underserved patient groups. In the first instance, The George Institute has partnered with Bupa to progress the development of a combination pill containing core recommended cardiovascular medicines (often called a “polypill”). This will be achieved through a new innovative joint venture – SmartGenRx – which will develop products designed to increase access to effective medicines and better health outcomes for a range of major cardiovascular conditions. The intention is to work with leading industry and government partners to develop innovative ways to ensure treatments are made available to those most in need.

The George Institute has conducted a large clinical research program that has shown polypill-based care produces better adherence and bigger risk reductions than usual care with multiple individual drugs. These benefits were observed in high income and low income countries. Since long-term use of recommended medicines is particularly low in emerging markets, polypills may have a particularly important role in the care of high-risk patients in these settings.